Tiotropium bromide inhalation - Pulmatrix

Drug Profile

Tiotropium bromide inhalation - Pulmatrix

Alternative Names: PUR-0200; PUR0217a; PUR0228a; PUR0228b; PUR0228c; PUR0230c; VR 410

Latest Information Update: 18 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pulmatrix
  • Developer Mylan; Pulmatrix
  • Class Antiasthmatics; Antibronchitics; Epoxy compounds; Esters; Small molecules; Thiophenes; Tropanes
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 13 Jun 2018 Pharmacodynamics and safety data from a phase I trial in Chronic obstructive pulmonary disease released by Pulmatrix
  • 07 Jun 2018 Pulmatrix and Vectura plan a phase I/II study in Chronic obstructive pulmonary disease by end-2018
  • 30 Sep 2017 Pulmatrix has patent protection for tiotropium bromide inhalation product for Chronic obstructive pulmonary disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top